Recent research has unveiled critical insights into how HIV-1 develops resistance to broadly neutralizing antibodies (bNAbs), a promising avenue for long-acting HIV treatments. Approximately 1-5% of HIV-1 patients generate these rare bNAbs, which can neutralize a significant portion of global HIV-1 isolates. A recent trial demonstrated that a single dose of two bNAbs maintained nearly undetectable viral loads in participants for up to 20 weeks, with one participant sustaining this effect for about a year. Despite this promise, the mechanisms by which HIV-1 escapes these antibodies remain poorly understood across diverse strains.
Researchers from The Rockefeller University have conducted extensive studies to map the escape pathways of HIV-1 from bNAbs. By employing thousands of viral selection experiments, they identified over 100 mutations that confer resistance to two specific bNAbs: 3BNC117 and 10-1074. This comprehensive approach, termed RISC (resistance identification via selection and cloning), revealed that a single amino acid change could often suffice for resistance, highlighting the adaptability of the virus.
The implications of these findings are significant for the development of effective therapies. Understanding the specific mutations that facilitate resistance can inform the design of bNAb treatments that are more robust against the diverse strains of HIV-1. As the researchers aim to identify additional resistance mutations and explore combination therapies, the potential for creating more effective treatment regimens increases, addressing the urgent need for durable solutions in HIV management.
Get started today with Solo access →
